Vaccine effectiveness against SARS-CoV-2 Delta and Omicron infection and infectiousness within households in the Netherlands between July 2021 and August 2022

Christina E. Hoeve, Brechje de Gier, Anne J. Huiberts, Hester E. de Melker, Susan J.M. Hahné, Susan van den Hof, Mirjam J. Knol
doi: https://doi.org/10.1101/2023.01.10.23284386

Article Information

doi 
https://doi.org/10.1101/2023.01.10.23284386
History 
  • January 11, 2023.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Christina E. Hoeve1,*,
  2. Brechje de Gier1,
  3. Anne J. Huiberts1,
  4. Hester E. de Melker1,
  5. Susan J.M. Hahné1,
  6. Susan van den Hof1 and
  7. Mirjam J. Knol1
  1. 1Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands
  1. ↵*Corresponding author; email: christel.hoeve{at}rivm.nl
Back to top
Posted January 11, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Vaccine effectiveness against SARS-CoV-2 Delta and Omicron infection and infectiousness within households in the Netherlands between July 2021 and August 2022
Christina E. Hoeve, Brechje de Gier, Anne J. Huiberts, Hester E. de Melker, Susan J.M. Hahné, Susan van den Hof, Mirjam J. Knol
medRxiv 2023.01.10.23284386; doi: https://doi.org/10.1101/2023.01.10.23284386
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area